Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Viatris's latest financial disclosures highlight a mix of positive and negative developments, resulting in mixed implications for potential investors.</li><li>In examining Viatris's performance for 2024 and their outlook for 2025, there are notable strategic strengths and ongoing challenges to consider.</li><li>In 2024, Viatris reported a modest revenue growth of 2% on a divestiture-adjusted operational basis, reaching approximately $14.7 billion, consistent with their guidance.</li></ul>

Viatris's latest financial disclosures highlight a mix of positive and negative developments, resulting in mixed implications for potential investors.In examining Viatris's performance for 2024 and their outlook for 2025, there are notable strategic strengths and ongoing challenges to consider.In 2024, Viatris reported a modest revenue growth of 2% on a divestiture-adjusted operational basis, reaching approximately $14.7 billion, consistent with their guidance.

Viatris Inc.: Expanding Footprint in China To Change The Game!

<ul><li>Viatris's Q3 2024 results showcased key elements both bolstering and challenging its financial position.</li><li>Notably, the company delivered significant revenue growth, with total revenues reaching $3.8 billion, a 3% increase on an operational basis.</li><li>Additionally, Viatris achieved its sixth consecutive quarter of growth in terms of adjusted EBITDA and adjusted earnings per share (EPS).</li></ul>

Viatris's Q3 2024 results showcased key elements both bolstering and challenging its financial position.Notably, the company delivered significant revenue growth, with total revenues reaching $3.8 billion, a 3% increase on an operational basis.Additionally, Viatris achieved its sixth consecutive quarter of growth in terms of adjusted EBITDA and adjusted earnings per share (EPS).

Viatris Inc.: Expansion of Innovative Portfolio As A Vital Factor Driving Growth! - Major Drivers

APAC IPOs & Placements, Aequitas Research

Akshat Shah

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Rubicon Research Limited / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/rubicon-research-limited" target="_blank" data-smartkarma-citation="entities:43796:1" rel="noopener">Rubicon Research Limited (1453591D IN)</a> is looking to raise about US$130m in its India IPO.</li>
<li>It is a pharmaceutical formulations company with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets, particularly, the United States.</li>
<li>In this note, we talk about the company’s historical performance.</li>
</ul>



Rubicon Research Limited (1453591D IN) is looking to raise about US$130m in its India IPO.
It is a pharmaceutical formulations company with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets, particularly, the United States.
In this note, we talk about the company’s historical performance.


Rubicon Research Pre-IPO - Robust Product Development Pipeline Driving Revenue Growth

<ul><li>Viatris has delivered a solid performance in the second quarter of 2024, marking the fifth consecutive quarter of operational revenue growth.</li><li>Under the leadership of CEO Scott Smith, the company, which was formed from the merging of Mylan and Upjohn, a division of Pfizer, has effectively integrated two global entities and streamlined its operations through strategic divestitures.</li><li>This strategic realignment has evidently positioned Viatris at a pivotal point for future growth, focusing strongly on expanding its innovative products alongside its stable base business.</li></ul>

Viatris has delivered a solid performance in the second quarter of 2024, marking the fifth consecutive quarter of operational revenue growth.Under the leadership of CEO Scott Smith, the company, which was formed from the merging of Mylan and Upjohn, a division of Pfizer, has effectively integrated two global entities and streamlined its operations through strategic divestitures.This strategic realignment has evidently positioned Viatris at a pivotal point for future growth, focusing strongly on expanding its innovative products alongside its stable base business.

Viatris Inc.: Unlocking The Dry Eye Disease Market With Tyrvaya! - Major Drivers

<ul><li>Viatris Inc. released its Q1 2024 earnings and demonstrated consistent execution against core business fundamentals.</li><li>These include maintaining base business stability, driving new product revenue, and focusing on key strategic initiatives that spur future growth.</li><li>Viatris announced its successful acquisition of Idorsia and its strategic R&D plans for the recent acquisitions – selatogrel and cenerimod.</li></ul>

Viatris Inc. released its Q1 2024 earnings and demonstrated consistent execution against core business fundamentals.These include maintaining base business stability, driving new product revenue, and focusing on key strategic initiatives that spur future growth.Viatris announced its successful acquisition of Idorsia and its strategic R&D plans for the recent acquisitions – selatogrel and cenerimod.

United States

Viatris Inc. operates as a pharmaceutical company. The Company produces medicines for patients across broad range of major therapeutic areas spanning both noncommunicable and infectious diseases. Viatris serves clients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Viatris (VTRS US)

Viatris Inc.: Expanding Footprint in China To Change The Game!

Viatris's latest financial disclosures highlight a mix of positive and negative developments, resulting in mixed implications for potential...

Baptista Research

Viatris Inc.: Expansion of Innovative Portfolio As A Vital Factor Driving Growth! - Major Drivers

Viatris's Q3 2024 results showcased key elements both bolstering and challenging its financial position. Notably, the company delivered...

Baptista Research

Rubicon Research Pre-IPO - Robust Product Development Pipeline Driving Revenue Growth

Rubicon Research Limited is looking to raise about US$130m in its India IPO. In this note, we talk about the company’s historical performance.

Akshat Shah

Viatris Inc.: Unlocking The Dry Eye Disease Market With Tyrvaya! - Major Drivers

Viatris has delivered a solid performance in the second quarter of 2024, marking the fifth consecutive quarter of operational revenue...

Baptista Research

Viatris Inc.: Unlocking The Dry Eye Disease Market With Tyrvaya! - Major Drivers

Viatris Inc. released its Q1 2024 earnings and demonstrated consistent execution against core business fundamentals. These include maintaining...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)